Cutler Group LP Atara Biotherapeutics, Inc. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 18, 2023	BUY	$1.5 - $3.04 $450 - $912	300 Added 25.0%	1,500 $2,000
Q1 2023 May 01, 2023	BUY	$2.8 - $5.46 $3,360 - $6,552	1,200 New	1,200 $3,000
Q2 2022 Aug 04, 2022	BUY	$4.69 - $9.84 $4,221 - $8,856	900 New	900 $7,000
Q4 2021 Jan 18, 2022	SELL	$14.7 - $19.89 $4,410 - $5,967	-300 Closed	0 $0
Q4 2020 Jan 21, 2021	SELL	$12.67 - $26.23 $2,534 - $5,246	-200 Reduced 40.0%	300 $5,000

Q3 2020 Oct 27, 2020	SELL	$11.92 - $15.87 $2,384 - $3,174	-200 Reduced 28.57%	500 $6,000
Q1 2020 May 07, 2020	BUY	$5.69 - $17.78 $1,138 - $3,556	200 Added 40.0%	700 $5,000
Q4 2017 Jan 17, 2018	SELL	$13.2 - $18.1 $27,720 - $38,010	-2,100 Reduced 80.77%	500 $9,000
Q3 2017 Oct 17, 2017	BUY	$13.25 - $17.05 $34,450 - $44,330	2,600	2,600 $43,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $781M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.